QINGDAO BAHEAL PHARMACEUTI

Qingdao Baheal Pharmaceutical remains flat but poised for upside as China tightens drug approvals, boosts R&D and expands markets—an attractive long‑term play in China’s pharma sector.

Qingdao Baheal Pharmaceutical shares trade flat at CNY 22.30, with a 14.6% dip since last month, amid mixed peer performance in China’s pharma sector.